Article Text

Download PDFPDF

Progression/remission of COVID-19: data-driven recommendations for repeating SARS-CoV-2 nucleic acid amplification tests
  1. Nathan Williams1,
  2. Reed Idriss2,
  3. Jessica Dodge1,
  4. Samuel Barasch1
  1. 1Pathology and Laboratory Medicine, Danbury Hospital, Danbury, Connecticut, USA
  2. 2Department of Emergency Medicine, Danbury Hospital, Danbury, Connecticut, USA
  1. Correspondence to Dr Samuel Barasch, Pathology and Laboratory Medicine, Danbury Hospital, Danbury, Connecticut, USA; samuel.barasch{at}


Aims This short study was performed to better understand the time frame associated with changes in SARS-CoV-2 nucleic acid testing and provide recommendations for repeat testing. Recommendations are useful as little guidance is available for repeat testing in patients being followed expectantly for changes in disease.

Methods A review of laboratory data of tests for SARS-CoV-2 nucleic acid was performed selecting patients who had changing results. Time between changes in test results was determined to provide guidance for repeat testing.

Results The Interquartile Range (IQR) of data for patients who had a negative to positive change in laboratory testing (progression) was 6–16 days (median=9 days). The IQR of data for patients who had a positive to negative change in test results (remission) was 9–21 days (median=14 days).

Conclusion Because sampling of the nares or nasopharynx can be variable, repeat testing should be performed swiftly when symptomatic patients are negative. The data in this short study vary widely, so authors recommend repeat testing during a period of time associated with the IQR or median (see results above).

  • virology
  • clinical audit
  • quality assurance
  • healthcare

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.
View Full Text

Statistics from


Laboratory testing for COVID-19 has taken a prominent position in the SARS-CoV-2 pandemic, and nucleic acid testing has been negative in some symptomatic patients1 and positive in some patients who are asymptomatic.1–3 Results which are discordant from the clinical picture are likely due to a combination of several factors including the following: viral prodromal/incubation period,1 4 5 sampling discordance from different swabbing techniques and clinical abilities,6 analytical differences between nucleic acid detection/instruments/methods or other technical analytical complications6 7 and changes in patient disease state.1 2 Given that analytical sensitivity is high with nucleic acid amplification (NAA, testing methodology available early in the pandemic), clinical and biological factors such as appropriate specimen collection technique, progression of disease and regression of disease can contribute to changes in values for the diagnostic nucleic amplification for SARS-CoV-2. This study was undertaken to assess prevalence of laboratory data changes in SARS-CoV-2 NAA tests, as well as time frames associated with these changes. Findings could guide testing for progression or remission of disease and may contribute to biological knowledge of the disease.


This study was reviewed by our institutional review board and received exempt determination for accessing and disclosing anonymised patient laboratory data. The laboratory information system was searched for SARS-CoV-2 NAA tests in inpatients and outpatients associated with Western Connecticut Health Network (WCHN) hospitals (Danbury, Connecticut; Norwalk, Connecticut; New Milford, Connecticut) through testing performed at WCHN Laboratories, Connecticut Department of Public Health Laboratory and Reference Laboratories between 1 March 2020 and 19 April 2020. All tests were based on presence of nucleic acid for SARS-CoV-2 in the patient nasopharynx or nasal cavity. Testing laboratory, test manufacturer and viral gene targets include the following: WCHN, Abbott ID NOW, RdRP gene; Connecticut Department of Public Health Laboratory, Centers for Disease Control and Prevention (CDC) primers, N1/N2/N3 genes; Sunrise Medical Laboratories, Roche Cobas 6800/8800, ORF1 and E genes.8–10 For testing performed on-site at hospitals, testing was performed according to manufacturer specifications. Prior to 6 April 2020, all samples were collected via nasopharyngeal swabs or nasal swabs and stored/transported to testing facilities in Universal Transport Media (UTM). Beginning on 6 April 2020, nasal swabs without UTM were tested on Abbott ID NOW analysers. Each test was performed on a separate sample. Patients with duplicate testing were identified. From the group of patients with duplicate testing, a group of patients with discordant results was identified. Result verified date was used to assign chronology. Number of days between discordant results was determined. Patients changing from a negative to positive result were classified as ‘progression’, while patients changing from positive to negative were classified as ‘remission.’ ‘Progression’ and ‘remission’ in this study refer to newly appearing positive results or newly appearing negative results. In this context, the terms ‘progression’ and ‘remission’ imply a change of laboratory testing from negative to positive or positive to negative. The number of days between the first positive or negative result and the first discordant result was recorded as the number of days to progression or remission. Patients with same day results which were discordant were recorded as 0 days between progression or remission. Figure 1 histogram was created with Microsoft Excel. R 4.0.0 was used to generate scatterplots and boxplots and statistical analysis.

Figure 1

Number of laboratory tests required before change in test results (ie, ‘progression’ or ‘remission’).


Results are summarised in table 1. 13 206 NAA tests were performed and resulted in the study time period. Most laboratory result dates were between 0 and 2 days following the order date with order date being shortly before date and time of specimen collection. The total number of tests represented 12 360 patients tested. Five hundred and ninety-one patients had 688 duplicate tests which were concordant. 118 patients had 158 discordant duplicate SARS-CoV-2 tests. Sixty-five patients with discordant tests were classified as ‘progression’, while 53 patients with discordant tests were classified as ‘remission’. Three patients had 0 days to progression and one patient had 0 days to remission. Most patients with change in laboratory values had a change after one test (figure 1). Seven patients were identified who had subsequent testing following a remission. Of these seven patients with remission and repeat testing, the repeat testing was negative in 6 of 7 patients. See table 2 for dates of testing for these patients. For patients with progression, the mean number of days was 10.4 (10.9 excluding days to progression of 0) and the median was 9 (figure 2). For patients with remission, the mean was 13.5 days (13.7 excluding days to remission of 0) and median was 14 days (figure 3).

Table 1

Summary of results

Table 2

Dates of testing for patients with a change from positive to negative NAA results with repeat testing following ‘remission’

Figure 2

Days between progression (switch from negative to positive SARS-CoV-2 test results). Box shows IQR and median. IQR, Interquartile Range; NAA, nucleic acid amplification.

Figure 3

Days between remission (switch from positive to negative SARS-CoV-2 results). Box shows IQR and median. IQR, Interquartile Range; NAA, nucleic acid amplification.


Recent guidance from the CDC has been released regarding a Symptom-Based Strategy to Discontinue Isolation for Persons with COVID-19.11 While the Symptom-Based strategy is appropriate for many patients, interim guidance from the CDC includes options for discontinuing isolation precautions for asymptomatic test-positive patients who are divided into two different strategies: time-based and test-based. Isolation times for patients who have never had any symptoms using the time-based strategy require 10 days since the positive test. With the test-based strategy, asymptomatic carriers can be cleared from isolation with two negative tests from different samples which are more than 24 hours apart (see CDC guidance for details).12 These recommendations highlight both the variability in viral shedding and sampling errors possible in affecting testing results.

In our study, same day repeat testing was a small proportion of patients who had a change in test results (0 days to progression/remission). These few patients were likely due to differences in nasopharyngeal swabbing technique rather than progression from a carrier state or remission of viral production in recovering patients. It is likely that some of the patients with change in laboratory results in the 1–2 day time frame may also represent a change in test results due to nasopharyngeal swabbing technique. Changes in laboratory results in the time period of 0–2 days may be due to an inadequately collected sample. Repeat sample collection with nasal/nasopharyngeal swab in a brief window of time is recommended to confirm a negative test.4 13 Little information is available regarding false-positive test results which could confound an early carrier/incubation/low symptom/convalescent carrier period in which patients lack symptoms and test positive.14 However, divergent coronavirus strains or phylogenetically similar viral genomes could be involved in a repeated positive test in the absence of symptoms.6 13 Presence of viral nucleic acid long after viral cultures can be recovered (ie, culture serves as an in vitro indication of in vivo organism viability), has been demonstrated and could be contributing to difficulties clearing patients from isolation with a nucleic acid test-based strategy.15 16

Although knowledge about viral incubation times is rapidly evolving and many studies have highly varied results, the data collected here are concordant with what is currently known about viral incubation times and postrecovery carriage times. The ‘progression’ data collected in this study overlap with studies which show viral incubation time of between 2 and 14 days.1 2 6 14 17 The ‘remission’ data collected in this study likewise suggest a carriage time following resolution of symptoms which extends for several weeks.1 15 16 However, both time to progression or time to remission, as determined by laboratory viral detection, can be influenced by lead time (ie, time from symptomatic disease onset prior to patient presenting for laboratory detection).

The data presented here represent both clinical variability of sample collection as well as biological behaviour of SARS-CoV-2 through the window of changes in laboratory testing. However, some recommendations on repeat testing can be made. For patients with high clinical suspicion and test results which are divergent from the clinical picture, swift repeat testing is recommended.6 13 If repeat testing is confirmatory, and an additional repeat test is required by the clinical circumstances, repeat testing after a period of time within the interquartile ranges of collected data, such as the median (figures 2 and 3) should be considered. Therefore, testing for progression following a repeat negative is recommended at 9 days (or between 6 and 16 days) and testing for remission following a repeat positive is recommended at 14 days (or between 9 and 21 days).

In conclusion, although some guidance can be drawn from these data for repeat testing, this study does not control for sampling of the nares, testing methodology, patient disease state or time of sampling. Long-term follow-up on a broader window of patients is not available at the time of writing this and would give a more accurate time frame for repeat testing. Additionally, correlation with serological testing could give these data both additional validity for recommending testing times and a deeper understanding of disease and immunological dynamics. Finally, clinical details surrounding the repeat testing are unavailable to the authors and would give a more thorough understanding of effective utilisation of testing for SARS-CoV-2.


View Abstract


  • Handling editor Tahir S Pillay.

  • Contributors All authors contributed to data collection, analysis, interpretation or writing of this submission.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Patient consent for publication Not required.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.